Cases & Deals

Avanir licenses D-DM from Concert for neurological disorders

Clients Avanir Pharmaceuticals, Inc.

Jones Day represented Avanir Pharmaceuticals, Inc. in its worldwide, exclusive license from Concert Pharmaceuticals to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurological and psychiatric disorders. Concert will receive upfront payment and is eligible to receive milestone payments and royalties.